Cecconi M, Ranza, R, Titton, DC, et al. - This study was intended to establish the incidence rate (IR) of serious infections in rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients on biologic drugs. Researchers recruited a total of 1,698 individuals (RA, 1121; SpA, 577) with rheumatic diseases who started the first biologic drug or a synthetic disease-modifying antirheumatic drug as a parallel control group. Between January 2009 and June 2015, this study concentrates on serious infectious adverse events (SIAEs) in RA and SpA individuals on biologic drugs compared with controls. In BIOBADABRASIL, compared with synthetic DMARDs, biologic drugs, particularly the subsequent TNFi, were correlated with a higher risk of serious infections. This study reported that corticosteroid intake and age represented risk factors for SIAEs. In Brazil, constant monitoring is needed to follow the safety profile of drugs in the clinical setting of rheumatic conditions.